Here is how Accolade (ACCD) and Casella (CWST) have performed compared to their sector so far this year.
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.
Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.
| - Industry | - Sector | Mr. Rajeev Singh CEO | NASDAQ (NGS) Exchange | US00437E1029 ISIN |
| United States Country | 2,400 Employees | - Last Dividend | - Last Split | 2 Jul 2020 IPO Date |
Accolade, Inc. is a company that stands at the forefront of delivering personalized and technology-driven solutions aimed at enhancing individuals' ability to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. Established in 2007, with its headquarters in Seattle, Washington, Accolade, Inc. has carved out a significant niche in the healthcare industry. Through its innovative approach, the company caters to employers seeking to provide their employees and their families with a centralized resource for all their health, healthcare, and benefits needs. This dedication to simplifying the healthcare experience for users makes Accolade, Inc. a pivotal player in the industry.
Accolade, Inc.'s offerings are a blend of technology, personal touch, and healthcare expertise. The company's products and services include: